Dexmedetomidine

Generic Name
Dexmedetomidine
Brand Names
Dexdor, Igalmi, Precedex, Dexmedetomidine Accord
Drug Type
Small Molecule
Chemical Formula
C13H16N2
CAS Number
113775-47-6
Unique Ingredient Identifier
67VB76HONO
Background

An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine.

Indication

Administered intravenously, dexmedetomidine is indicated for the sedation of initially intubated and mechanically ventilated patients during treatment in intensive care settings, and for the sedation of non-intubated patients prior to and/or during surgery and other procedures. It is also available as a buccally- or sublingually-administered dissolvable film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder.

Associated Conditions
Agitation, Alcohol Withdrawal Syndrome
Associated Therapies
-
Clinical Trials
Related News

Dexmedetomidine Premedication in Hypertensive Patients

Phase 3
Completed
Conditions
Hypertension
Interventions
Drug: Dexmedetomidine
Drug: Midazolam
First Posted Date
2014-02-10
Last Posted Date
2014-02-10
Lead Sponsor
Duzce University
Target Recruit Count
162
Registration Number
NCT02058485
Locations
🇹🇷

Duzce University Medicine School, Anesthesiology and Reanimation Department, Duzce, Turkey

Anesthesia in Patients With Mitochondrial Disease

First Posted Date
2014-02-04
Last Posted Date
2024-08-28
Lead Sponsor
The University of Texas Health Science Center, Houston
Target Recruit Count
19
Registration Number
NCT02053766
Locations
🇺🇸

University of Texas Health Science Center at Houston, Houston, Texas, United States

Effect of the Addition of Dexmedetomidine to Bupivacaine During Supraclavicular Brachial Plexus Blockade

First Posted Date
2014-01-30
Last Posted Date
2014-11-10
Lead Sponsor
TC Erciyes University
Target Recruit Count
44
Registration Number
NCT02049970
Locations
🇹🇷

Erciyes University Medical Faculty, Kayseri, Turkey

Effects of Dexmedetomidine During IRE Procedures for Solid Tumours

Phase 4
Completed
Conditions
Cancer of Liver
Cancer of Pancreas
Interventions
Drug: Dexmedetomidine
First Posted Date
2014-01-23
Last Posted Date
2015-10-20
Lead Sponsor
Uppsala University Hospital
Target Recruit Count
30
Registration Number
NCT02044224
Locations
🇸🇪

Uppsala University Hospital, Uppsala, Sweden

Effect of Dexmedetomidine on Bispectral Index and Propofol Requirements During Different Menstrual Cycle

Phase 4
Completed
Conditions
Abnormal Menstrual Cycle
Interventions
Drug: dexmedetomidine
First Posted Date
2014-01-14
Last Posted Date
2014-01-14
Lead Sponsor
Fudan University
Target Recruit Count
110
Registration Number
NCT02035930

Can Dexmedetomidine For Procedural Sedation In Knee Arthroplasty Reduce Postoperative Pain? A Randomized Control Study

First Posted Date
2014-01-01
Last Posted Date
2016-06-20
Lead Sponsor
University of Saskatchewan
Target Recruit Count
40
Registration Number
NCT02026141
Locations
🇨🇦

Regina General Hospital, Regina, Saskatchewan, Canada

Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours

First Posted Date
2013-12-20
Last Posted Date
2014-12-17
Lead Sponsor
Uppsala University Hospital
Target Recruit Count
50
Registration Number
NCT02016391
Locations
🇸🇪

Uppsala University Hospital, Uppsala, Sweden

Efficacy of Peritonsillar Dexmedetomidine Infiltration for Postadenotonsillectomy Pain

First Posted Date
2013-12-17
Last Posted Date
2013-12-17
Lead Sponsor
TC Erciyes University
Target Recruit Count
71
Registration Number
NCT02013570

Small-dose Dexmedetomidine Effects on Recovery Profiles of Supratentorial Tumors Patients From General Anesthesia

First Posted Date
2013-12-11
Last Posted Date
2014-01-14
Lead Sponsor
China Medical University, China
Target Recruit Count
150
Registration Number
NCT02007798
Locations
🇨🇳

Yue Yun, Shenyang, Liaoning, China

Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery

Phase 4
Completed
Conditions
Heart Disease
Interventions
Drug: Dexmedetomidine
Drug: Placebo
First Posted Date
2013-12-09
Last Posted Date
2021-04-06
Lead Sponsor
The Cleveland Clinic
Target Recruit Count
798
Registration Number
NCT02004613
Locations
🇺🇸

Cleveland Clinic Main, Cleveland, Ohio, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy